

Supplemental Table for:
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors
Stephen Leong et al.

Table S1. Alterations detected in the qRT-PCR six-gene mutation panel mutation assay

Gene	Mutation count	Alterations detected
<i>PIK3CA</i>	17	R88Q, N345K, C420R, E542K, E545A, E545G, E545D, E545K, Q546E, Q546K, Q546L, Q546R, M1043I, H1047L, H1047R, H1047Y, G1049R
<i>KRAS</i>	18	G12A, G12C, G12D, G12F, G12R, G12S, G12V, G13A, G13C, G13D, G13R, G13S, G13V, Q61H (2), Q61K, Q61L, Q61R
<i>EGFR</i>	43	G719A, G719C, G719S, G768I, T790M, L858R (2), L861Q, Exon 20 insertions (5), Exon 19 deletions (30)

Abbreviations: *EGFR*, epidermal growth factor receptor; *KRAS*, Kirsten rat sarcoma viral oncogene homolog; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; qRT-PCR, quantitative reverse transcription polymerase chain reaction.